Programme Titles Presenters
Sunday, 2nd December 2018
11:00-13:30 Registration
Harvey Morse Auditorium Lobby
13:30-13:40 Welcome and introduction
Harvey Morse Auditorium
13:40-14:30 Opening Keynote
Harvey Morse Auditorium
[K01] Sally Temple, Neural Stem Cell Institute, USA - Neural stem cells as a foundation for central nervous system repair
Harvey Morse Auditorium
14:30-17:15 Session 1: Modeling and Treating Neurological Disorders
Harvey Morse Auditorium
14:30-15:00 [INV01] Clive Svendsen, Cedars-Sinai Medical Center, USA - Development of a combined stem cell and gene therapy approach for neurodegenerative diseases
Harvey Morse Auditorium
15:00-15:15 [ST01] - Cell-Based therapy to suppress neuroinflammation and mitigate neuronal injury
Harvey Morse Auditorium
15:15-15:45 Refreshment break
Taper Roof Top
15:45-16:15 [INV02] Roger Barker, University of Cambridge, UK
Harvey Morse Auditorium
16:15-16:45 [INV03] Steven Goldman, University of Rochester Medical Center, USA
Harvey Morse Auditorium
16:45-17:00 [ST02] - Pluripotent stem cells and mouse-human chimeras for modeling the development and progression of human cancer in vivo
Harvey Morse Auditorium
17:00-17:15 Discussion
Harvey Morse Auditorium
17:15-18:30 Welcome Reception
Taper Roof Top
Monday, 3rd December 2018
08:15-08:45 Breakfast workshop by Nikon
Harvey Morse Auditorium
09:00-12:30 Session 2: HSC-based gene therapy
Harvey Morse Auditorium
09:00-09:30 [INV04] Alessandra Biffi, Dana-Farber/Boston Children's Hospital, USA
Harvey Morse Auditorium
09:30-10:00 [INV05] Donald Kohn, University of California, Los Angeles, USA - Hematopoietic stem cell gene therapy
Harvey Morse Auditorium
10:00-10:30 Refreshment break
Taper Roof Top
10:30-10:45 [ST03] - Long-term persistence and function of Hematopoietic Stem Cell-derived Chimeric Antigen Receptor T cells against HIV infection
Harvey Morse Auditorium
10:45-11:15 [INV06] Paula Cannon, University of Southern California, USA
Harvey Morse Auditorium
11:15-11:30 Discussion
Harvey Morse Auditorium
11:30-12:15 Meet the editors
Harvey Morse Auditorium
12:15-13:15 Lunch
Taper Roof Top
13:15-14:15 Poster Session 1
Briskin Executive Conference and HMCC 4&5
14:15-17:45 Session 3: Tissue engineering and cell replacement
Harvey Morse Auditorium
14:15-14:45 [INV07] Chuck Murry, University of Washington, USA
Harvey Morse Auditorium
14:45-15:15 [INV08] Christine Mummery, Leiden University Medical Center, Netherlands - Challenges using hiPSC as cardiovascular disease models and for drug target discovery
Harvey Morse Auditorium
15:15-15:30 [ST04] - MAP4K4 mediates human cardiac muscle cell death: Human pluripotent stem cell-derived cardiomyocytes for target validation and drug developmen
Harvey Morse Auditorium
15:30-15:45 [ST05] - Modeling müllerian high-grade serous carcinogenesis using BRCA1 patient derived induced pluripotent stem cells
Harvey Morse Auditorium
15:45-16:15 Refreshment break
Taper Roof Top
16:15-16:30 [ST06] - Modeling progressive fibrosis with pluripotent stem cells identifies an anti-fibrotic small molecule
Harvey Morse Auditorium
16:30-17:00 [INV09] Douglas Melton, Harvard University, USA - Making pancreatic islets for diabetics
Harvey Morse Auditorium
17:00-17:30 [INV10] Tim Kieffer, University of British Columbia, Canada - Cell therapy for diabetes: Opportunities and challenges
Harvey Morse Auditorium
17:30-17:45 Discussion
Harvey Morse Auditorium
19:00-21:30 Meet the speakers dinner
Sofitel Los Angeles at Beverly Hills
Tuesday, 4th December 2018
08:15-08:45 Breakfast workshop by Agilent
Harvey Morse Auditorium
09:00-12:30 Session 4: Cell and Immunotherapy
Harvey Morse Auditorium
09:00-09:30 [INV11] Carl June, University of Pennsylvania, USA
Harvey Morse Auditorium
09:30-10:00 [INV12] Jacques Galipeau, University of Wisconsin, USA - Mesenchymal Stromal Cells - navigating perils on the pathway to marketing approval
Harvey Morse Auditorium
10:00-10:15 [ST07] - Stem cell-engineered invariant natural killer T cells for cancer immunotherapy
Harvey Morse Auditorium
10:15-10:45 Refreshment break
Taper Roof Top
10:45-11:15 [INV13] Gay Crooks, University of California, Los Angeles, USA - From human pluripotent stem cells to engineered T cells
Harvey Morse Auditorium
11:15-11:45 [INV14] - Michele De Luca, University of Modena and Reggio Emilia, Italy - Combined cell and gene therapy of junctional epidermolysis
Harvey Morse Auditorium
11:45-12:00 Discussion
Harvey Morse Auditorium
12:00-13:15 Lunch
Taper Roof Top
13:15-14:15 Poster Session 2
Briskin Executive Conference and HMCC 4&5
14:15-16:30 Session 5: Clinical Progress
Harvey Morse Auditoriu
14:15-14:45 [INV15] Catriona Jamieson, University of California, San Diego, USA
Harvey Morse Auditorium
14:45-15:00 [ST08] - Autologous iPS cell therapy for macular degeneration: From bench-to-bedside
Harvey Morse Auditorium
15:00-15:15 [ST09] - iPSCs-based modeling sporadic ALS and screening therapeutic drug: Development of a new clinical trial
Harvey Morse Auditorium
15:15-15:45 Refreshment break
Taper Roof Top
15:45-16:15 [INV16] Jane Lebkowski, Regenerative Patch Technologies, USA - Subretinal implantation of a bioengineered embryonic stem cell-derived retinal pigment epithelium monolayer in dry age related macular degeneration
Harvey Morse Auditorium
16:15-16:30 [ST10] - Pharmacogenetics and drug discovery for anthracycline-induced cardiotoxicity enabled by sinoatrial node-like cells derived from human pluripotent stem cells
Harvey Morse Auditorium
16:30-17:20 Closing Keynote
Harvey Morse Auditorium
[K02] Hongkui Deng, Peking University, China
Harvey Morse Auditorium
17:20-17:30 Conference closing remarks
Harvey Morse Auditorium
Registration handled on behalf of Elsevier Ltd by Oxford Abstracts
Copyright 2018 Elsevier Limited. Privacy | Terms | Cookies
Oxford Abstracts. Privacy | Terms | Cookies